Mithra Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Christophe Marechal

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	4.1yrs
Promedio de permanencia en la Junta Directiva	2.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Christophe Marechal

7.3yrs

Permanencia

Mr. Christophe Maréchal has been the Chief Financial Officer of Mithra Pharmaceuticals SA since February 23, 2017 and also serves as its Co-Chief Executive Officer since March 5, 2024. Mr. Maréchal serves...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christophe Marechal	Co-CEO & CFO	7.3yrs	sin datos	sin datos
Xavier Paoli	COO & Co-CEO	less than a year	sin datos	sin datos
Graham Dixon	Chief Scientific Officer	4.8yrs	sin datos	sin datos
Alex Sokolowski	Head of Investor Relations	no data	sin datos	sin datos
Fanny Rozenberg	Secretary of the Board & General Counsel	no data	sin datos	sin datos
Fanny Storms	Compliance Officer	no data	sin datos	sin datos
Frederique Depraetere	Communication Director	no data	sin datos	sin datos
Catherine Lejeune	HR Director	no data	sin datos	sin datos
Jean-Manuel Fontaine	Chief Commercial & External Affairs Officer	3.3yrs	sin datos	0.000040% € 6.0
Jean-Michel Foidart	President of the Scientific Advisory Board & Executive Director	no data	€7.12k	0.029% € 4.4k
Christophe Saillez	Head of Global Regulatory Affairs	no data	sin datos	sin datos
Maud Jost	Head of Program & Project Management	no data	sin datos	sin datos

4.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0R91 se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Michel Foidart	President of the Scientific Advisory Board & Executive Director	7.7yrs	€7.12k	0.029% € 4.4k
Jacques Platieau	Independent & Non-Executive Director	1.3yrs	€25.00k	sin datos
Valerie Gordenne	Non-Executive Director	2.4yrs	€20.00k	0.042% € 6.3k

2.4yrs

Permanencia media

Junta con experiencia: La junta directiva de 0R91 no se considera experimentada (2.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Mithra Pharmaceuticals Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Mithra Pharmaceuticals SA Announces CEO Changes

Mithra Appoints Christian Homsy as Chairman

Mithra Approves Board Appointments

Mithra Pharmaceuticals SA, Annual General Meeting, May 25, 2023

Less than half of directors are independent

High number of new directors

Recent updates

Forecast to breakeven in 2026

New major risk - Financial position

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Mithra Pharmaceuticals SA Announces CEO Changes

Mithra Pharmaceuticals SA to Report First Half, 2024 Results on Sep 26, 2024

Mithra Pharmaceuticals SA to Report Fiscal Year 2023 Results on Mar 08, 2024

No longer forecast to breakeven

No longer forecast to breakeven

New minor risk - Market cap size

First half 2023 earnings released

New major risk - Negative shareholders equity

Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023

New major risk - Revenue and earnings growth

Mithra Pharmaceuticals SA has completed a Follow-on Equity Offering in the amount of €20 million.

Mithra Pharmaceuticals SA announced that it has received €20 million in funding from Armistice Capital, LLC

Forecast breakeven date pushed back to 2025

New minor risk - Market cap size

Mithra Announces New Positive Preclinical Data from Csf-1R Inhibitor Program

Mithra Appoints Christian Homsy as Chairman

Mithra Approves Board Appointments

Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Mithra Pharmaceuticals SA to Report Fiscal Year 2022 Final Results on Apr 18, 2023

Mithra Pharmaceuticals SA, Annual General Meeting, May 25, 2023

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

First half 2022 earnings released: €0.69 loss per share (vs €1.28 loss in 1H 2021)

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mithra Pharmaceuticals SA announced that it expects to receive €23.500005 million in funding

High number of new directors

Full year 2021 earnings: Revenues miss analyst expectations

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

Forecast to breakeven in 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Full year 2020 earnings released: €2.25 loss per share (vs €0.70 loss in FY 2019)

Full year 2020 earnings released

Revenue misses expectations

New 90-day high: €23.33

Investor sentiment improved over the past week

Mithra and Searchlight Pharma Announces Nextstellis Approval in Canada

Mithra Pharmaceuticals SA to Report Fiscal Year 2020 Results on Mar 09, 2021

Mithra Announces Executive Changes

Mithra Pharmaceuticals SA, Annual General Meeting, May 20, 2021

New 90-day high: €18.50

New 90-day low: €16.53

New 90-day low: €16.89

New 90-day low - €17.08

Mithra Pharmaceuticals SA has completed a Follow-on Equity Offering in the amount of €64.999988 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media